This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Quality of Care  • Patient Safety/ Medical Error  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

How Tight Is Right and How to Get There

David M. Nathan, MD

Arch Intern Med. 2008;168(19):2064-2066.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The worldwide epidemic of type 2 diabetes mellitus¹ has spurred the development of numerous new medications directed at controlling glycemia. Since 1995, 6 new classes of medications (-glycosidase inhibitors, meglitinides, thiazolidinediones, glucagon-like peptide analogues, amylin analogues, and dipeptidyl-peptidase IV inhibitors) have been approved for use in the United States. In addition to these new classes of antidiabetic medications, most of which will soon include more than 1 approved drug, new variations of older drugs, such as the insulin analogues, have been developed and brought to market. Finally, metformin hydrochloride, a biguanide that had been in popular use worldwide for 30 years, was approved for use in the United States in 1994, after concern regarding its potential for lactic acidosis was assuaged.

The explosive development of new drugs has been ignited not only by the enormous profits that stand to be made (eg, before metformin lost . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Elizabeth Selvin, Shari Bolen, Hsin-Chieh Yeh, Crystal Wiley, Lisa M. Wilson, Spyridon S. Marinopoulos, Leonard Feldman, Jason Vassy, Renee Wilson, Eric B. Bass, and Frederick L. Brancati
Arch Intern Med. 2008;168(19):2070-2080.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al.
Cobitz and Ambery
Diabetes Care 2009;32:e58-e58.
FULL TEXT